High-speed railway (HSR) brings convenience to peoples' lives and is generally considered as one of the most sustainable developments for ground transportation. One of the important parts of HSR construction is the signaling system, which is also called the "operation control system," where wireless communications play a key role in the transmission of train control data. We discuss in detail the main differences in scientific research for wireless communications between the HSR operation scenarios and the conventional public land mobile scenarios. The latest research progress in wireless channel modeling in viaducts, cuttings, and tunnels scenarios are discussed. The characteristics of nonstationary channel and the line-of-sight (LOS) sparse and LOS multiple-input-multiple-output channels, which are the typical channels in HSR scenarios, are analyzed. Some novel concepts such as composite transportation and key challenging techniques such as train-to-train communication, vacuum maglev train techniques, the security for HSR, and the fifth-generation wireless communications related techniques for future HSR development for safer, more comfortable, and more secure HSR operation are also discussed.
In the epithelium of Drosophila during tissue elongation, contractile forces in follicle cells can oscillate. These oscillations correlate with increasing tension in the epithelium from egg chamber growth. A mathematical model is proposed to explain the observed oscillations, together with a mechanism of active regulation of cellular contractile forces.
Renal dysfunction predicts all-cause mortality in general population. However, the prevalence of renal insufficiency and its relationship with mortality in cancer patients are unclear.We retrospectively studied 9465 patients with newly diagnosed cancer from January 2010 to December 2010. Renal insufficiency was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration equation. The hazard ratio (HR) of all-cause mortality associated with baseline eGFR was assessed by Cox regression.Three thousand sixty-nine patients (32.4%) exhibited eGFR <90 mL/min/1.73 m2 and 3% had abnormal serum creatinine levels at the time of diagnosis. Over a median follow-up of 40.5 months, 2705 patients (28.6%) died. Compared with the reference group (eGFR ≥ 60 mL/min/1.73 m2), an elevated all-cause mortality was observed among patients with eGFR < 60 mL/min/1.73 m2 stratified by cancer stage in the entire cohort, the corresponding hazard ratios were 1.87 (95% CI, 1.41–2.47) and 1.28 (95% CI, 1.01–1.62) for stage I to III and stage IV, respectively. However, this relationship was not observed after multivariate adjustment. Subgroup analysis found that eGFR < 60 mL/min/1.73 m2 independently predicted death among patients with hematologic (adjusted HR 2.93, 95% CI [1.36–6.31]) and gynecological cancer (adjusted HR 2.82, 95% CI [1.19–6.70]), but not in those with other cancer. Five hundred fifty-seven patients (6%) had proteinuria. When controlled for potential confounding factors, proteinuria was a risk factor for all-cause mortality among patients in the entire cohort, regardless of cancer stage and eGFR values. When patients were categorized by specific cancer type, the risk of all-cause death was only significant in patients with digestive system cancer (adjusted HR, 1.85 [1.48–2.32]).The prevalence of renal dysfunction was common in patients with newly diagnosed cancer. Patients with eGFR < 60 mL/min/1.73 m2 or proteinuria were associated with increased risk for all-cause mortality, this relation depended on cancer site.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.